01 de Noviembre del 2019
On October 25, 2019, Novitium Pharma LLC (Novitium) issued a voluntary recall of Ranitidine 150mg capsules, and 300mg capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.
The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.
Description |
Strength |
Type |
Pack Size |
NDC |
Ranitidine Capsules 150mg |
150 mg |
Rx |
60 ct bottle |
70954-001-20 |
Ranitidine Capsules 150mg |
150 mg |
Rx |
500 ct bottle |
70954-001-40 |
Ranitidine Capsules 300mg |
300 mg |
Rx |
30 ct bottle |
70954-002-10 |
Ranitidine Capsules 300mg |
300 mg |
Rx |
100 ct bottle |
70954-002-40 |
Additional information is available on the FDA's website:
Última actualización: 08 de Diciembre del 2023